Table 1.

The characteristics of patients

Characteristics, n (%)	Total (n = 17)	Apatinib (n = 13)	Anlotinib (n = 4)	P
Age, median(range), yr	59 (35–73)	60 (35–73)	58 (49–66)	0.881*
Sex, male/female	10/7 (58.8 vs. 41.2)	7/6 (53.8 vs. 46.2)	2/2 (50.0 vs. 50.0)	1.000**
ECOG PS				1.000**
0	6 (35.3)	5 (38.5)	1 (25.0)
1	11 (64.7)	8 (61.5)	3 (75.0)
Smoking status				0.538**
Never	12 (70.6)	10 (76.9)	2 (50.0)
Former or current	5 (29.4)	3 (23.1)	2 (50.0)
WHO histology				0.307**
Squamous cell carcinoma	10 (58.8)	6 (46.2)	4 (100.0)
Undifferentiated carcinoma	3 (17.6)	3 (23.1)	0 (0.0)
Unavailable	4 (23.5)	4 (30.8)	0 (0.0)
Masaoka-Koga stage				1.000**
IVA	1 (5.9)	1 (7.7)	0 (0.0)
IVB	16 (94.1)	12 (92.3)	4 (100.0)
Number of prior treat-line				1.000**
1	10 (58.8)	8 (61.5)	2 (50.0)
>1	7 (41.2)	5 (38.5)	2 (50.0)
Surgical Procedures				0.541**
Yes	3 (17.6)	3 (23.1)	0 (0.0)
No	14 (82.4)	10 (76.9)	4 (100.0)
Lung metastasis				1.000**
Yes	13 (76.5)	10 (76.9)	3 (75.0)
No	4 (23.5)	3 (23.1)	1 (25.0)
Liver metastasis				0.584**
Yes	6 (35.3)	4 (30.8)	2 (50.0)
No	11 (64.7)	9 (69.2)	2 (50.0)

*p value calculated by t test

**p value calculated by Fisher’s exact test